MedPath

Molecular Fingerprinting in Cancer Detectio

Recruiting
Conditions
C34
C61
C50
C67
C00-C14
C18
C22
C25
C95
J44.1
Registration Number
DRKS00019844
Lead Sponsor
udwig-Maximilians-Universität München (LMU)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
38000
Inclusion Criteria

Informed consent, = 18 years, healthy subject, or one of the eligible benign or malignant diseases.

Exclusion Criteria

Multiple cancers, any cancer therapy within the last two years, no blood draw possible, participant noncompliance

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary objective of this study is the accuracy of IMF diagnosis for nine cancer entities, assessed by comparison with all data available to the investigator. A diagnoses is regarded as correct if IMF and clinical routine assessing all available data coincide with regard to the nine tumor entities of interest.
Secondary Outcome Measures
NameTimeMethod
1) Capability to reproduce or improve the results of the pilot study<br>2) Capability of IMF to recognize sub-types of tumors and tumor stages<br>3) Capability of IMF to distinguish between patients with any tumors on the one hand and healthy subjects and patients with benign diseases on the other one<br>4) Reliability of IMF with regard to sensibility, specificity, PNT and PPT<br>5) Accuracy of IMF as compared with a conventional FTIR Analyzer<br>6) Gain additional information on IMFs: defining cancer-independent and cancer-dependent parts of IMFs in longitudinal observations
© Copyright 2025. All Rights Reserved by MedPath